患者中巴酸血水平:与有效性和耐受性的相关性?
Bernhard J Steinhoff1,2, Dimitra Georgiou1, Daniel Dietmann1
1Kork Epilepsy Center, Kehl-Kork, 77694 Kehl, Germany.
Journal of clinical medicine
|May 25, 2024
概括
在患者中,血中赛诺巴酸盐的含量差异很大,剂量,控制或不良事件之间没有明确的相关性. 治疗药物监测可能有助于个性化塞诺巴治疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 神经学 神经学
- 治疗的方法 治疗
背景情况:
- 塞诺巴被批准用于对其他治疗无反应的成年人的焦点发作.
- 关键试验表明,巴的高疗效和无发作率.
- 现实世界的研究也表明了塞诺巴马特的有效性.
研究的目的:
- 调查没有发作的患者与没有反应的患者 (PWE) 的血水平.
- 将经历不良事件的PWE与没有经历不良事件的PWE的血水平进行比较.
- 确定血水平是否与疗效和耐受性相关.
主要方法:
- 从101名接受稳定辅助赛诺巴治疗的成人PWE收集了血液样本.
- 评估每日剂量,同时服用的药物,控制和不良事件.
- 在没有发作和没有反应的子组之间,以及在有和没有不良事件的子组之间比较血中赛诺巴酸盐水平.
主要成果:
- 在无发作和无反应的PWE之间,每日剂量或血中赛诺巴酸盐水平没有显著差异.
- 带有和没有不良事件的PWE之间没有剂量或血水平的显著差异.
- 观察到治疗范围的广泛个体间变异性,一些患者在低剂量/水平下实现了无发作或经历了不良事件,而另一些患者没有反应或容忍高剂量/水平.
结论:
- 由于广泛的个体变异性,无法定义巴的一般治疗范围.
- 治疗性药物监测可用于个性化治疗.
- 需要进行进一步的研究,以了解同时服用的药物对锡诺巴水平和疗效的影响.
相关概念视频
Drug Concentration Versus Time Correlation
735
The plasma drug concentration-time curve is a crucial tool in pharmacokinetics, representing the drug's concentration in plasma at different time intervals post-administration. This curve illustrates the drug's journey from absorption into the systemic circulation, distribution to body tissues, and eventual elimination through excretion or biotransformation.
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
Two pivotal parameters are the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). The MEC is the...
735
Antiepileptic Drugs: Potassium Channel Activators
173
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
173
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
286
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
286
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
124
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
124
Electroconvulsive Therapy
36
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
36


